Explorative Study of AZD1305 in Atrial Fibrillation Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Atrial Fibrillation
Interventions
DRUG

AZD1305

AZD1305 loading dose 250 mg + 125 mg evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2

DRUG

AZD1305

AZD1305 loading dose 500 mg + placebo evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2

DRUG

Placebo

Placebo corresponding to AZD1305 loading dose + evening dose on Study Day 1, maintenance dose twice daily from Study Day 2

Trial Locations (18)

Unknown

Research Site, Aalborg

Research Site, Copenhagen

Research Site, Esbjerg

Research Site, Hvidovre

Research Site, Silkeborg

Research Site, Svendborg

Research Site, Oslo

Research Site, Rud

Research Site, Tynset

Research Site, Bytom

Research Site, Warsaw

Research Site, Moscow

Research Site, Saint Petersburg

Research Site, Košice

Research Site, Nitra

Research Site, Nové Zámky

Research Site, Rimavská Sobota

Research Site, Gothenburg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY